Determining Risk in Latent Tuberculosis
Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Latent Tuberculosis
Phase: N/A
Status: Terminated
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID) Official(s) and/or principal investigator(s): Clifton E Barry, Ph.D., Principal Investigator, Affiliation: National Institute of Allergy and Infectious Diseases (NIAID)
Summary
Background:
- Tuberculosis (TB) is a leading cause of death worldwide. Those who are exposed to the TB
bacteria but have not become sick are said to have latent TB. Many people with latent TB
will not get sick from it, but some people will develop active TB and become sick. Much is
known about how to treat and diagnose active TB, but little is known about the best way to
treat latent TB. Researchers also want to know more about the risk that latent TB will
develop into active TB, and whether it is possible to test for this risk.
Objectives:
- To test possible methods of determining a person s risk for developing active TB.
Eligibility:
- Individuals between 20 and 60 years of age who (1) have active TB, (2) were exposed to
someone with active TB in the past 9 months, or (3) have not been exposed to TB.
Design:
- Participants will be separated into groups based on their exposure to TB.
- Healthy participants who were not exposed to TB will answer questions about their
medical history. They will also provide blood and urine samples.
- Participants who have active TB will have a physical exam and medical history. They
will provide blood, urine, and sputum samples, and will have a chest x-ray. They will
be treated with the standard of care for active TB. Some participants with active TB
may have additional tests as part of this study.
- Participants who were exposed to TB and have latent TB will have a physical exam and
medical history. They will provide blood, urine, and sputum samples, and will have a
chest x-ray. They will be asked to return for five more clinic visits over the next 12
months to repeat these tests. They may also have additional chest imaging studies
depending on the study needs.
- Some of the exposed participants may have been exposed to drug-resistant TB. These
participants will receive the drug isoniazid to take on a regular schedule to help
prevent the latent TB from becoming active TB.
Clinical Details
Official title: Risk Stratification in Latent Tuberculosis: PET/CT Findings in TB Contacts
Study design: Time Perspective: Prospective
Primary outcome: To estimate the rate of PET plus CXR at baseline among all study participants.
Secondary outcome: To estimate the rate of PET+/CT- at baseline among all study participants.To estimate the rate of regression of PET plus scans (to normal) at 3 and 12 months among the untreated subjects (n=30).
Detailed description:
The efficacy of treating tuberculin skin test (TST) positive, or interferon gamma release
assay (IGRA) positive, contacts of tuberculosis (TB) cases to prevent progression to disease
is well established. However the length of treatment, and the toxicity associated with the
currently used regimens, means that the risk may outweigh the benefit and treatment
completion rates are poor. In addition, no proven regimens are available for contacts of
multidrug resistant tuberculosis (MDR-TB) cases. Because as few as 2% of contacts develop
active TB over 1 year and no surrogate markers are available, drug trials to assess novel
treatments typically require thousands of subjects followed up for many years.
(18F)-fluoro-2-deoxy-D-glucose positron emission tomography/computer tomography (FDG-PET/CT)
may prove a useful surrogate for more targeted chemoprophylaxis as well as a means to
rapidly evaluate novel prophylactic regimes in future studies.
Up to 40% of immune-sensitized TB contacts with normal chest radiographs (CXR) have
abnormalities on conventional chest CT. FDG-PET/CT not only will allow characterization of
the metabolic activity of these lesions but is also likely to reveal significantly increased
metabolic activity within regional lymph nodes that may otherwise be anatomically normal.
Based on previous studies, we predict that up to 65% of contacts will have combined chest
PET/CT abnormalities and that up to 50% of contacts who are treated, will have increased FDG
uptake that will resolve with treatment. By contrast, PET screening studies demonstrate
abnormal pulmonary FDG uptake occurs in 0. 9% of healthy individuals.
The development of biomarkers more predictive of disease progression is also highly
desirable, but for similar reasons evaluating them is challenging. This novel approach of
using FDG-PET/CT to benchmark the dynamic immunological, transcriptional, or metabolic
changes that occur early in tuberculosis infection, we hope will accelerate biomarker
discovery. In this study we propose to evaluate these predictions in order to lay the
foundation for future studies.
Eligibility
Minimum age: 20 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
- INDEX CASES:
INCLUSION CRITERIA:
1. Either confirmed sputum smear positive and culture positive for M. tb within the last
12 months OR sputum smear positive and genotypically confirmed M. tb with culture
awaited
2. Age greater than or equal to 20 years old
20 Smear Positive Pulmonary TB Biomarker Index Case Controls:
INCLUSION CRITERIA:
1. Genotypically confirmed sputum smear positive pulmonary tuberculosis
2. Culture awaited or confirmed Mtb
3. Not commenced anti-tuberculous therapy
4. Age greater than or equal to 20 years old
EXCLUSION CRITERIA:
1. Age > 60 years old
2. Known diagnosis of chronic inflammatory condition (e. g. Sarcoid, RA, connective
tissue disorder) or on immunosuppressive medication
WITHDRAWAL CRITERIA:
1) Culture negative for M. tb
QF-GIT Positive Contacts:
INCLUSION CRITERIA:
1. Contacts of index case
2. QF-GIT positive
3. Age greater than or equal to 20 years old
4. Normal CXR
EXCLUSION CRITERIA:
1. Exposure to an index case who commenced treatment for a current episode of TB (one
that was not successfully treated, per WHO definition) more than 15 months ago
2. Previously diagnosed or treated TB
3. Symptoms or signs of active TB
4. Symptoms or signs of acute illness
5. CXR suggestive of active tuberculosis or parenchymal abnormalities known or suspected
to be caused by alternative pathology
6. HIV positive or other significant immunocompromise
7. Age > 60
8. Smoker > 30 pack years
9. Previously diagnosed malignancy
10. Previously diagnosed chronic lung infection (e. g., non tuberculosis mycobacteria
[NTM], Fungal, Paragonimus)
11. Known diagnosis of chronic inflammatory condition associated with pulmonary pathology
(e. g., Sarcoidosis, RA, Wegener s granulomatosis, bronchiectasis)
12. Inhaled or systemic steroid use within previous 2 weeks (subject may return for
enrollment 2 weeks after last dose) and need for ongoing steroid therapy
13. Breast feeding, pregnant, or planning pregnancy
14. Anticipated poor compliance
Locations and Contacts
National Medical Center, Seoul, Korea, Republic of
Additional Information
Related publications: Banura C, Mirembe FM, Katahoire AR, Namujju PB, Mbonye AK, Wabwire FM. Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer. 2011 Jul 12;6(1):11. doi: 10.1186/1750-9378-6-11. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010 Aug 20;59(32):1018-23.
Starting date: January 2012
Last updated: October 23, 2014
|